Figure 3.

Impact of therapy on CAR T-cell activity. Treatment prior to leukapheresis, bridging therapy administered to the patient during the production of CAR T cells, and lymphodepleting chemotherapy prior to CAR T-cell infusion can have an impact on the antitumor effect of CAR T cells. In addition, in the setting of clinical trials, several agents are administered after CAR T-cell infusion (e.g., IMiDs and CD38-targeting antibodies) to enhance CAR T-cell efficacy or improve CAR T-cell persistence.